Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

Similar documents
Nash with cirrhosis icd 10

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

Liver Disease NASH/Fibrosis Model

Hepatocellular carcinoma

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Supplementary Figure 1

Liver Cancer And Tumours

V8 NEXUS. Glyco Liver Profile NA2 NA3 NA2FB NGA2F. The next generation in non-invasive liver diagnostics INFLAMMATION FIBROSIS CIRRHOSIS HCC

Liver Pathology in the 0bese

The role of Hepatitis C Virus in hepatocarcinogenesis

Hepatocellular Carcinoma (HCC): Burden of Disease

Evaluation of Liver Mass Lesions. American College of Gastroenterology 2013 Regional Postgraduate Course

Translating Research into Clinical Practice: Strategies Against Hepatocellular Cancer

THBA Platform - Bile acid imbalance

Improving Access to Quality Medical Care Webinar Series

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

ADME in NAFLD: Genes and Big Jeans Increase the Risk of Adverse Drug Reactions. Drug-Induced Liver Injury

1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:

Cell Therapy: The Future Of Medicine?

Triple Negative Breast Cancer

Jung Han Kim, PhD Project 1 Project 2

Figure S1. IRF5 mrna expression is not expressed modulated by steatosis grade in

SUPPLEMENTARY INFORMATION

NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES

NASH Bench to Bedside

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

Carcinogenesis. Carcinogenesis. 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples

Biochemistry of Cancer and Tumor Markers

FOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB

Defining the gold standard in biomarker validation for NASH

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Liver Fat Quantification

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

Autoimmune Hepatitis Events Easl

Index. Note: Page numbers of article titles are in boldface type.

As outlined under External contributions (see appendix 7.1), the group of Prof. Gröne at the

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Invited Re vie W. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver diseases

Hepatocellular Carcinoma. Markus Heim Basel

UMHS-PUHSC JOINT INSTITUTE

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Spring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017

Alcoholic hepatitis is a drug-induced disorder

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

(A) PCR primers (arrows) designed to distinguish wild type (P1+P2), targeted (P1+P2) and excised (P1+P3)14-

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz October 11, 2013

Understanding your FibroScan Results

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine

Pitfalls in the diagnosis of well-differentiated hepatocellular lesions

Metabolic Syndrome and HCC. Jacob George

Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease.

Forward-looking Statements

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Automatic Pathology Software for Diagnosis of Non-Alcoholic Fatty Liver Disease

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

DISEASE ETIOLOGY. Dynamic condition Morpho-functional alteration of one or more organ/tissue Acute or chronic Localized or systemic

Non-Alcoholic Fatty Liver Disease (NAFLD)

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF

Molecular signature for management of hepatocellular carcinoma

Histopathology of Wooden Breast

Type 2 Diabetes and Cancer: Is there a link?

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Supplementary Information Titles Journal: Nature Medicine

Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with

Regulatory update from Europe:

Quantification of early stage lesions for loss of p53 should be shown in the main figures.

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Tissue repair. (3&4 of 4)

Section C. Biomarkers of Early Biological Effect and Altered Structure and Function

LIVER PATHOLOGY. Thursday 28 th November 2013

Supplemental Figure 1

Treatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Non-Alcoholic Fatty Liver Disease

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS

Steatotic liver disease

Project report October 2012 March 2013 CRF fellow: Principal Investigator: Project title:

Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Cancer and the Cell Cycle was developed by OpenStax College, licensed by Rice University, and available on the Connexions website, is available under

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

Clinical Trials & Endpoints in NASH Cirrhosis

Transcription:

University of Windsor Scholarship at UWindsor UWill Discover Undergraduate Conference UWill Discover 2016 Mar 29th, 4:00 PM - 5:00 PM Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression Carlee Stoyanovich University of Windsor, stoyanoc@uwindsor.ca Bre-Anne Fifield University of Windsor, fifield@uwindsor.ca Lisa Porter University of Windsor, lporter@uwindsor.ca Follow this and additional works at: https://scholar.uwindsor.ca/uwilldiscover This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License Stoyanovich, Carlee; Fifield, Bre-Anne; and Porter, Lisa, "Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression" (2016). UWill Discover Undergraduate Conference. 3. https://scholar.uwindsor.ca/uwilldiscover/2016/session9/3 This Event is brought to you for free and open access by the UWill Discover! at Scholarship at UWindsor. It has been accepted for inclusion in UWill Discover Undergraduate Conference by an authorized administrator of Scholarship at UWindsor. For more information, please contact scholarship@uwindsor.ca.

Spy1 and Hepatocellular Carcinoma Progression: Exploring a Link in a Murine Model Presented by : Carlee Stoyanovich Honors Thesis Project 2016

Hepatocellular Carcinoma (HCC) The most aggressive and prevalent form of primary liver cancer In men, it is the 5 th most common cancer and in women it is the 7 th worldwide Current treatments are invasive and include: transplantation, resection, ablation and chemotherapy The 5-year survival rate is 20% http://www.hopkinsmedicine.org/liver_tumor_center/conditions/cancerous_liver_tumors/hepatocellular_carcinoma.html

The Progression Diet/Lifes tyle Factors Hepatitis B/C Fatty Liver Disease Steatohepatitis Fibrosis Cirrhosis? HCC Alcoholism + Fibrosis F http://www.bionapcfa.com/2015/11/can-fite-advances-cf102-in-massive-nash.html

A Protective Mechanism G2 M G1 S p53 p53 Tumor suppressor Halts the cell cycle during unfavorable conditions Regulates cell death (apoptosis) Aids in DNA repair In HCC normally inactivated or mutated Spy1 Speed up cell division Override cell cycle barriers Enhance stemness in cell populations Known role in breast and brain cancers

MMTV-Spy1 Mouse B6CBAF1/J genetic background Designed to study breast cancer in mice models Constitutively overexpress Spy1 in the mammary gland

Percentage of Mice With Liver Tumours HCC in the Spy1 Mouse Model MMTV-Spy1 male mice with high levels of Spy1 have significantly more HCC than their male littermate controls. 45 * 40 35 30 25 20 15 10 5 0 Cntl MMTV-Spy1 *p=0.046302 MMTV-Spy1 n=23 B6CBAF1/J n=23 Fifield (2014)

A Potential Mechanism? M G1 p53 Fatty Liver Spy1 p53 G2 S Spy1 overrides p53 HCC Does an increase in Spy1 levels predispose the liver to HCC development?

Objectives Further characterize the MMTV-Spy1 liver phenotype. Develop a model to look at HCC progression in wildtype mice. Quantify Spy1 protein levels in the wild-type damaged mice livers. Monitor fat accumulation as well as p53 and TNFalpha levels in the mice livers.

Effects of Spy1 on Liver Morphology Normal hepatocytes Large vacuoles Disordered cell structure Healthy liver +1yr control mouse Fat accumulation +1yr MMTV-Spy1 mouse HCC +1yr MMTV-Spy1 mouse

Fat Accumulation in MMTV-Spy1 Mice 10 month control mouse 10 month MMTV-Spy1 mouse

Spy1 Increases Indices of Cell Division The percentage of bi-nucleated cells are significantly higher in control mice. +1 yr control mouse

The Progression in MMTV-Spy1 Mice + Fibrosis Increased fat accumulation? Increased HCC Decreased bi-nucleated cells

The Progression in MMTV-Spy1 Mice + Fibrosis Trichrome stain of +1yr MMTV-Spy1 mouse Collagen

The Methionine Choline Deficient (MCD) Diet Produces the most severe NASH phenotype in the shortest timeframe Causes increased fat accumulation in the hepatocytes Induces: Inflammation Apoptosis Oxidative damage Fibrosis Increased serum alanine aminotransferase levels

MCD Progression Oil Red O Staining TNF-alpha Levels Inflammatory Phase Fat Accumulation Trichrome Stain Fibrotic Phase Day 0 Day 2 1 week 6 weeks Stress Response When do endogenous Spy1 levels peak?

The MCD Diet Experiment Healthy Mouse Fat Accumulation Fibrosis Day 0- Mice are placed on diets Day 2 1 week 6 weeks Collect Liver Tissue MCD Diet Amino Acid Control Diet Same genetic background as MMTV-Spy1 mice Male mice between 8-12 weeks of age

Tissue Collection and Analysis Formalin Flash Frozen in 4% Liquid Nitrogen paraformaldehyde H+E Staining Immunohistochemistry Analyze gene expression Quantify protein levels Monitor fat accumulation

Area Stained Fat Accumulation in MCD Mice 250000 200000 * Day 2 control Day 2 MCD 150000 100000 * * 50000 1 week control 1 week MCD 0 Control Day 2 1 week 6 week MCD 6 week control 6 week MCD

Fibrosis in MCD Mice MCD mice had clear collagen deposition as compared to the controls. 6 week control 6 week MCD

p53 Protein (densitometry corrected for actin) Spy1 Protein (densitometry corrected for actin) Spy 1 and p53 Levels 3.5 MCD Diet (NASH) 3 2.5 Cntl Diet MCD Diet Day 2 1 Week Day 2 1 Week Spy1 2 Activate p53 Actin 1.5 1 0.5 0 0.07 0.06 Control Day 2 1 week 6 week MCD Halt the cell cycle 0.05 0.04 0.03 Apoptosis 0.02 0.01 0 Control Day 2 1 week 6 week MCD

TNF-alpha vs GAPDH TNF-alpha Gene Expression MCD Diet (NASH) Inflammation TNF-alpha activation Relative Quantification log 10 2 1.5 1 0.5 0-0.5-1 -1.5-2 Control Day 2 1 week 6 week MCD * -2.5

MCD Mice Progression Inflammatory Phase Fibrotic Phase Fat Accumulation Healthy Mouse Day 0 Day 2 1 week 6 weeks Stress Response Fat Accumulation Spy1 Protein p53 Protein TNF-alpha Gene Expression Collagen Deposition

Revised Timeline of Progression Spy1 as a prognostic indicator Healthy Liver NAFLD NASH Proliferation p53 Spy1 Fibrosis Cirrhosis HCC

Balance in the Face of Damage Proliferation/ Regeneration Fibrosis Stressed Liver Restores damaged hepatocytes Compensatory hyperplasia Allows for regeneration Maintains overall integrity of the organ Inflammation Formation of scar tissue Deposit collagen and fibrin

Does Proliferation Favor HCC Over Fibrosis? In response to an increase in fat accumulation and damage to hepatocytes, Spy1 will be up-regulated to increase regeneration and proliferative ability and decrease fibrosis. Spy1 Stressed Liver

Future Steps Developing a Spy1 driven mouse and follow it s progression on the MCD diet Spy1 Stressed Liver

Acknowledgements Thank you to my wonderful supervisor, Dr. Lisa Porter and to my mentor Dr. Bre-Anne Fifield! Thank you to the entire Porter Lab who have given me so much support and guidance! Thank you to our funding agencies: